IP Library › Granted Patent US 8,105,615
Granted Patent B2
US 8,105,615 · App. 10/862,213 · Granted Jan 31, 2012

Lactoferrin as an adjuvant in cancer vaccines

Assignee: Agennix Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,105,615
App. No.
10/862,213
Granted
Jan 31, 2012
Kind
B2
Abstract

The present invention relates to methods of treating cancer by administering a composition of lactoferrin (LF) in combination with cancer vaccines.

Claims (4)

1. A method of treating cancer comprising the step of administering to a subject a cancer immunotherapy and an adjuvant, wherein said adjuvant is a human lactoferrin composition that is administered orally for gastrointestinal delivery in an amount sufficient to provide an improvement in the cancer in said subject.

2. The method of claim 1 , wherein the cancer is breast cancer.

3. The method of claim 1 , wherein the cancer immunotherapy comprises DNA-based immunotherapy that comprises administration of a nucleic acid encoding a cancer antigen.

4. The method of claim 1 , wherein said lactoferrin composition is dispersed in a pharmaceutically acceptable carrier.

Assignments (2)
SECURITY AGREEMENT Recorded Mar 16, 2009
From: AGENNIX INCORPORATED
To: GPC BIOTECH AG
Reel/Frame 022399/0104 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2004
From: VARADHACHARY, ATUL; PERICLE, FEDERICA
To: AGENNIX INCORPORATED
Reel/Frame 015193/0873 →
Continuity (3)
Provisional Application 60476318 · Jun 6, 2003
Provisional Application 60498236 · Aug 27, 2003
Related Publication 20050019342A1 · Jan 27, 2005